

NANOPARTICLES IN BIOTECHNOLOGY, DRUG DEVELOPMENT AND DRUG DELIVERY



BIO113A
September 2012

Jackson Highsmith
Project Analyst

ISBN: 0-89336-119-4

bcc | Research
Market Forecasting

BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481
866-285-7215, 781-489-7301
www.bccresearch.com
Custom Reports: carol.laverty@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	1
STUDY GOALS AND OBJECTIVES	1
REASONS FOR DOING THE STUDY	1
SCOPE OF REPORT	1
INTENDED AUDIENCE	2
METHODOLOGY AND INFORMATION SOURCES	2
ANALYST CREDENTIALS	3
RELATED BCC REPORTS	3
BCC ON-LINE SERVICES	3
DISCLAIMER	4
CHAPTER 2 SUMMARY	6
<i>SUMMARY TABLE GLOBAL MARKET FOR NANOPARTICLES IN BIOTECHNOLOGY AND PHARMACEUTICALS, THROUGH 2017 (\$ MILLIONS)</i>	6
<i>SUMMARY FIGURE GLOBAL MARKET FOR NANOPARTICLES IN BIOTECHNOLOGY AND PHARMACEUTICALS, 2010-2017 (\$ MILLIONS)</i>	7
CHAPTER 3 OVERVIEW	9
NANOPARTICLE OVERVIEW	9
<i>TABLE 1 DESCRIPTION OF NANOPARTICLES USED IN DRUG DELIVERY AND DIAGNOSTIC IMAGING</i>	10
LIPOSOMES	10
NANOSHELLS	11
QUANTUM DOTS	11
SUPERPARAMAGNETIC NANOPARTICLES	11
DENDRIMERS	11
NANORODS	11
BRIEF HISTORY OF NANOPARTICLES	12
NANOPARTICLES IN BIOTECHNOLOGY	12
<i>TABLE 2 APPLICATION OF NANOPARTICLES IN BIOTECHNOLOGY</i>	13
NANOPARTICLES IN DRUG DEVELOPMENT	13
<i>TABLE 3 APPLICATION OF NANOPARTICLES IN DRUG DEVELOPMENT</i>	14
NANOPARTICLES IN DRUG DELIVERY SYSTEMS	14
<i>TABLE 4 APPLICATION OF NANOPARTICLES IN DRUG DELIVERY SYSTEMS</i>	15
<i>TABLE 5 NANOPARTICLE DRUG DELIVERY SYSTEMS</i>	16
NANOPARTICLES IN DIAGNOSTIC IMAGING	16
<i>TABLE 6 NANOPARTICLES USED FOR IN VIVO DIAGNOSTIC IMAGING</i>	18
MAJOR PLAYERS IN NANOPARTICLE DRUG DELIVERY FIELD	18
<i>TABLE 7 MAJOR PLAYERS IN NANOPARTICLE DRUG FIELD</i>	19
<i>TABLE 8 MAJOR PLAYER COMPANY REVENUES FOR NANOPARTICLE DRUGS, THROUGH 2017 (\$ MILLIONS)</i>	20
CHAPTER 4 GLOBAL MARKET FOR NANOPARTICLES IN LIFE SCIENCE	22
<i>TABLE 9 GLOBAL MARKET FOR NANOPARTICLES IN BIOTECHNOLOGY AND PHARMACEUTICALS, THROUGH 2017 (\$ MILLIONS)</i>	22
GLOBAL MARKET FOR NANOPARTICLES IN BIOTECHNOLOGY	22

TOPIC	PAGE NO.
<i>TABLE 10 GLOBAL REVENUES BIOTECHNOLOGY APPLICATIONS OF NANOPARTICLES, THROUGH 2017 (\$ MILLIONS)</i>	23
GLOBAL MARKET FOR NANOPARTICLES IN DRUG DEVELOPMENT	23
<i>TABLE 11 GLOBAL MARKET FOR NANOPARTICLES IN DRUG DEVELOPMENT AND FORMULATION, THROUGH 2017 (\$ MILLIONS)</i>	24
GLOBAL MARKET FOR NANOPARTICLES IN DRUG DELIVERY SYSTEMS	24
<i>TABLE 12 GLOBAL REVENUES FROM NANOPARTICLES IN DRUG DELIVERY SYSTEMS, THROUGH 2017 (\$ MILLIONS)</i>	25
GLOBAL MARKET FOR NANOPARTICLES IN DIAGNOSTIC IMAGING	25
<i>TABLE 13 GLOBAL REVENUES FROM NANOPARTICLES IN DIAGNOSTIC IMAGING SYSTEMS, THROUGH 2017 (\$ MILLIONS)</i>	25
CHAPTER 5 NANOPARTICLES STRUCTURE	28
ADOPTION OF NANOPARTICLES IN APPLIED MARKETS	28
<i>TABLE 14 NANOPARTICLE STRUCTURE AND PROPERTIES</i>	28
FULLERENES, CARBON TUBES AND BUCKY BALLS	29
LIQUID CRYSTALS	29
LIQUID CARRIERS	29
LIPOSOMES	30
DENDRIMERS	30
CHITOSAN AND ALGINATE	31
NANOCRYSTALS	31
QUANTUM DOTS	32
SUPERPARAMAGNETIC NANOPARTICLES	32
CHAPTER 6 NANOPARTICLE PRODUCTION	35
METHOD OF NANOPARTICLE FORMATION	35
SELF-ASSEMBLY PRODUCTION	36
METHODS OF STABILIZATION	37
METHODS OF DRUG INTRODUCTION	37
POLYMERIC NANOPARTICLES	37
MICELLES	38
LIPOSOMES	38
<i>TABLE 15 SAMPLE OF DRUGS DELIVERED THROUGH LIPOSOME NANOTECHNOLOGY</i>	39
GOLD AND SILICON NANOPARTICLES	39
DENDRIMERS	40
METHODS OF LOADING BIOLOGICAL MOLECULES INTO NANOPARTICLES	40
NANOCRYSTAL DRUGS	41
<i>TABLE 16 APPROVED NANOCRYSTAL DRUGS</i>	42
PROBLEM WITH LARGE-SCALE NANOPARTICLE PRODUCTION	42
CHAPTER 7 NANOPARTICLES IN BIOTECHNOLOGY	45
<i>TABLE 17 NANOPARTICLES IN BIOTECHNOLOGY APPLICATIONS</i>	45
RESEARCH AND DEVELOPMENT	45
STEM CELL RESEARCH	46
CELLULAR REPAIR	47
<i>IN VITRO</i> IMAGING	48
PARAMAGNETIC AND SUPERPARAMAGNETIC NANOPARTICLES	49

TOPIC	PAGE NO.
BIOSENSORS AND QUANTUM DOTS	49
QUANTUM DOTS	49
BIOSENSORS	50
<i>TABLE 18 NANOBIOSENSOR TECHNOLOGY UNDER DEVELOPMENT</i>	51
CHAPTER 8 NANOPARTICLES IN DRUG DEVELOPMENT AND FORMULATION	53
<i>TABLE 19 NANOPARTICLES IN DRUG DEVELOPMENT APPLICATIONS</i>	53
BIOSEPARATIONS	53
<i>TABLE 20 MONOCLONAL ANTIBODY (MAB) DRUGS WITH POTENTIAL FOR USE IN NANOPARTICLE DELIVERY SYSTEMS</i>	54
RAPID DRUG ANALYSIS	57
REMOVAL OF IMPURITIES AND TOXINS	57
USING NANOPARTICLES TO INCORPORATE INSOLUBLE DRUGS	58
<i>TABLE 21 SOLID LIPID NANOPARTICLE-REFORMATTED DRUGS</i>	59
SCREENING/PROFILING DRUG CANDIDATES	59
COMBINING ANTIBODIES AND DRUGS INTO NANOPARTICLES	60
GOLD AND SILVER NANOPARTICLES IN BIOMEDICINE	60
DNA NANOPARTICLE DEVELOPMENT OF DNA-SPECIFIC DRUGS	62
CHAPTER 9 NANOPARTICLES IN DRUG DELIVERY SYSTEMS	66
NANOPARTICLES IN DRUG DELIVERY APPLICATIONS	66
<i>TABLE 22 NANOPARTICLES IN DRUG DELIVERY APPLICATIONS</i>	66
DESIGNING A NANOPARTICLE DRUG DELIVERY SYSTEM	67
NANOPARTICLE DRUG STABILITY	67
SIZE HOMOGENEITY OF NANOPARTICLE PREPARATIONS	68
DRUG LOADING OF NANOPARTICLES	69
DRUG RELEASE FROM NANOPARTICLE	70
EXTERNAL TRIGGERS FOR RELEASING DRUG FROM NANOPARTICLES	71
BINDING/INCORPORATION OF BIOMOLECULES TO NANOPARTICLES	72
NANOPARTICLE TOXICITY	74
LARGE-SCALE MANUFACTURING	76
METHODS OF ADMINISTRATION OF NANOPARTICLE DRUGS	78
<i>TABLE 23 STANDARD ROUTES OF DRUG ADMINISTRATION</i>	78
ORAL ADMINISTRATION	78
INJECTION ADMINISTRATION	79
TRANSDERMAL PATCH	79
<i>TABLE 24 NANOPARTICLE TRANSDERMAL PATCH PRODUCTS</i>	79
IMPLANTATION ADMINISTRATION	80
INHALATION ADMINISTRATION	81
<i>NANOPARTICLES SUITABLE FOR DRUG DELIVERY SYSTEMS</i>	81
<i>TABLE 25 TYPES OF NANOPARTICLES SUPPLIED IN DRUG DELIVERY SYSTEMS</i>	82
LIPID-BASED NANOPARTICLES	82
NANOCRYSTALS	83
MICELLE NANOPARTICLES	84
DENDRIMERS NANOPARTICLES	84
POLYMERIC NANOPARTICLES	85
METAL-BASED NANOPARTICLES	85
BIOLOGICAL MACROMOLECULAR NANOPARTICLES	87

TOPIC	PAGE NO.
MESOPOROUS NANOPARTICLES	89
NANOCRYSTALS	90
<i>TABLE 26 NANOCRYSTAL DRUGS APPROVED BY THE FDA</i>	91
NANOPARTICLE DRUG DELIVERY SYSTEM CURRENTLY AVAILABLE	91
ANTIBIOTIC NANOPARTICLES	91
ANTI-TUMOR AND SMALL MOLECULE DELIVERY BY NANOPARTICLE	93
RELEASE OF ANTI-CANCER DRUGS FROM NANOPARTICLES	97
BIOMACROMOLECULES DELIVERED BY NANOPARTICLES	99
NANOPARTICLE COATINGS FOR DRUG DELIVERY SYSTEMS	102
REMOVAL OF NANOPARTICLES FROM THE BODY	103
RENAL CLEARANCE	103
<i>TABLE 27 MECHANISMS FOR REMOVAL OF NANOPARTICLES FROM THE BODY</i>	104
CHAPTER 10 IN VITRO AND IN VIVO DIAGNOSTIC IMAGING	106
<i>IN VITRO</i> IMAGING	106
NANOPARTICLES IN DIAGNOSTIC IMAGING	106
<i>TABLE 28 NANOPARTICLE CONTRAST MEDIA USED FOR IN VIVO DIAGNOSTIC IMAGING</i>	107
CHAPTER 11 BIOMEDICAL NANOPARTICLE PRODUCTS	110
CURRENT FDA-APPROVED NANOPARTICLE DRUG PRODUCTS	110
<i>TABLE 29 CURRENT FDA-APPROVED NANOPARTICLE DRUG DELIVERY SYSTEMS</i>	110
<i>TABLE 30 FDA-APPROVED DRUGS SPECIFICALLY FOR CANCER TREATMENT</i>	112
<i>TABLE 31 FDA-APPROVED DRUGS FOR CENTRAL NERVOUS SYSTEM DISEASES</i>	113
MAJOR PLAYERS IN NANOPARTICLE DRUG DELIVERY SYSTEMS	114
MAJOR PLAYERS IN NANOPARTICLE DRUG DELIVERY SYSTEMS	114
<i>TABLE 32 MAJOR PLAYERS IN NANOPARTICLE DRUG DEVELOPMENT AND FORMULATION MARKET</i>	114
COMPANY PIPELINES FOR NANOPARTICLE DRUG DELIVERY	115
<i>TABLE 33 COMPANY PIPELINE FOR CARDIOVASCULAR NANOPARTICLE DRUGS</i>	115
<i>TABLE 34 COMPANY PIPELINE FOR CNS DISEASE NANOPARTICLE DRUGS</i>	117
<i>TABLE 35 COMPANY PIPELINE FOR GI DISEASE NANOPARTICLE DRUGS</i>	119
<i>TABLE 36 COMPANY PIPELINE FOR INFECTIOUS DISEASE NANOPARTICLE DRUGS</i>	120
<i>TABLE 37 COMPANY PIPELINE FOR CANCER NANOPARTICLE DRUGS</i>	124
<i>TABLE 38 COMPANY PIPELINE FOR OPHTHALMIC NANOPARTICLE DRUGS</i>	126
<i>TABLE 39 COMPANY PIPELINE FOR AUTOIMMUNE DISEASE NANOPARTICLE DRUGS</i>	128
DRIVERS OF NANOPARTICLE PRODUCTS AND MARKETING	129
LIMITERS OF NANOPARTICLE PRODUCT DEVELOPMENT AND MARKETING	130
CHAPTER 12 GLOBAL MARKET FOR NANOPARTICLE DRUGS AND DELIVERY SYSTEMS	132
THE GLOBAL MARKET	132
<i>TABLE 40 GLOBAL MARKET FOR NANOPARTICLE DRUGS AND DIAGNOSTIC IMAGING, THROUGH 2017 (\$ MILLIONS)</i>	132
<i>TABLE 41 GLOBAL MARKET FOR NANOPARTICLE DRUG DEVELOPMENT AND FORMULATION AND DRUG DELIVERY SYSTEMS, THROUGH 2017 (\$ MILLIONS)</i>	133
<i>TABLE 42 GLOBAL MARKET FOR DIAGNOSTIC IMAGING AND IN VITRO IMAGING, THROUGH 2017 (\$ MILLIONS)</i>	133
CHAPTER 13 CLINICAL TRIALS OF NANOPARTICLE DRUGS AND DRUG DELIVERY SYSTEMS	136

TOPIC	PAGE NO.
<i>TABLE 43 CLINICAL TRIALS FOR NANOPARTICLE DRUGS AND DRUG DELIVERY SYSTEMS</i>	136
<i>TABLE 44 CLINICAL TRIALS FOR NANOPARTICLE DRUGS AND DRUG DELIVERY SYSTEMS</i>	137
<i>TABLE 45 CLINICAL TRIALS FOR NANOPARTICLE DRUGS AND DRUG DELIVERY SYSTEMS</i>	140
CHAPTER 14 PATENTS, LICENSING, MERGERS AND ACQUISITIONS	143
<i>TABLE 46 MAJOR LICENSING, COLLABORATIVE PARTNERSHIPS AND MERGER AND ACQUISITION ACTIVITIES</i>	143
NANOPARTICLE PATENTS	147
<i>TABLE 47 GLOBAL PERCENTAGE SHARE OF PATENTS ISSUED BY GEOGRAPHY, FROM 2008 TO 2011</i>	147
U.S. PATENTS FOR NANOPARTICLES DRUG DEVELOPMENT	148
<i>TABLE 48 U.S. PATENTS FOR NANOPARTICLE DRUG DEVELOPMENT</i>	148
U.S. PATENTS FOR NANOPARTICLE DRUG DELIVERY	148
<i>TABLE 49 U.S. PATENTS FOR NANOPARTICLE DRUG DELIVERY</i>	148
QUANTUM DOT PATENTS	152
<i>TABLE 50 U.S. PATENTS FOR QUANTUM DOT TECHNOLOGY APPLIED TO MEDICAL APPLICATIONS</i>	152
CHAPTER 15 COMPANY PROFILES	155
ABRAXIS BIOSCIENCES, INC	155
PRODUCTS	155
STRATEGY	155
ABRAXIS PHARMACEUTICAL PRODUCTS	155
PRODUCTS	156
STRATEGY	156
ACCESS PHARMA, INC.	156
PRODUCTS	157
STRATEGY	157
ALNYLAM PHARMACEUTICALS, INC.	157
PRODUCTS	157
STRATEGY	157
AMAG PHARMACEUTICALS, INC.	158
PRODUCTS	158
STRATEGY	158
APHIOS CORPORATION	158
PRODUCTS	159
ASKLEPIOS BIOPHARMACEUTICAL, INC.	159
PRODUCTS	159
STRATEGY	160
ASTRAZENECA PHARMACEUTICALS, PLC	160
PRODUCTS	160
STRATEGY	160
BIND BIOSCIENCES, INC	160
PRODUCTS	161
STRATEGY	161
CERULEAN PHARMA INC.	161
PRODUCTS	162
STRATEGY	162

TOPIC	PAGE NO.
CONVATEC	162
PRODUCTS	162
STRATEGY	162
DEBIOTECH, S.A.	163
PRODUCTS	163
STRATEGY	163
ELAN PHARMACEUTICALS, INC.	163
PRODUCTS	164
STRATEGY	164
FLAMEL TECHNOLOGIES, INC	164
PRODUCTS	165
STRATEGY	165
GE GLOBAL RESEARCH	165
PRODUCTS	165
STRATEGY	166
MAGFORCE NANOTECHNOLOGIES AG	166
PRODUCTS	166
STRATEGY	166
MIV THERAPEUTICS INC.	167
PRODUCTS	167
STRATEGY	167
NANOCARRIER CO., LTD.	167
PRODUCTS	168
STRATEGY	168
NANO INTERFACE TECHNOLOGY, INC	168
PRODUCTS	168
STRATEGY	168
NANOSPHERE, INC.	169
PRODUCTS	169
STRATEGY	169
NOVARTIS INTERNATIONAL AG	169
PRODUCTS	170
STRATEGY	170
PHARMASOL CORPORATION	170
PRODUCTS	170
STRATEGY	171
SKYEPHARMA, PLC	171
PRODUCTS	171
STRATEGY	172
STARPHARMA HOLDINGS, LTD	172
PRODUCTS	172
STRATEGY	172
TALON THERAPEUTICS, INC.	173
PRODUCTS	173
STRATEGY	173
T2 BIOSYSTEMS INC.	173
PRODUCTS	174

	TOPIC	PAGE NO.
	STRATEGY	174

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL MARKET FOR NANOPARTICLES IN BIOTECHNOLOGY AND PHARMACEUTICALS, THROUGH 2017 (\$ MILLIONS)	6
TABLE 1 DESCRIPTION OF NANOPARTICLES USED IN DRUG DELIVERY AND DIAGNOSTIC IMAGING	10
TABLE 2 APPLICATION OF NANOPARTICLES IN BIOTECHNOLOGY	13
TABLE 3 APPLICATION OF NANOPARTICLES IN DRUG DEVELOPMENT	14
TABLE 4 APPLICATION OF NANOPARTICLES IN DRUG DELIVERY SYSTEMS	15
TABLE 5 NANOPARTICLE DRUG DELIVERY SYSTEMS	16
TABLE 6 NANOPARTICLES USED FOR IN VIVO DIAGNOSTIC IMAGING	18
TABLE 7 MAJOR PLAYERS IN NANOPARTICLE DRUG FIELD	19
TABLE 8 MAJOR PLAYER COMPANY REVENUES FOR NANOPARTICLE DRUGS, THROUGH 2017 (\$ MILLIONS)	20
TABLE 9 GLOBAL MARKET FOR NANOPARTICLES IN BIOTECHNOLOGY AND PHARMACEUTICALS, THROUGH 2017 (\$ MILLIONS)	22
TABLE 10 GLOBAL REVENUES BIOTECHNOLOGY APPLICATIONS OF NANOPARTICLES, THROUGH 2017 (\$ MILLIONS)	23
TABLE 11 GLOBAL MARKET FOR NANOPARTICLES IN DRUG DEVELOPMENT AND FORMULATION, THROUGH 2017 (\$ MILLIONS)	24
TABLE 12 GLOBAL REVENUES FROM NANOPARTICLES IN DRUG DELIVERY SYSTEMS, THROUGH 2017 (\$ MILLIONS)	25
TABLE 13 GLOBAL REVENUES FROM NANOPARTICLES IN DIAGNOSTIC IMAGING SYSTEMS, THROUGH 2017 (\$ MILLIONS)	25
TABLE 14 NANOPARTICLE STRUCTURE AND PROPERTIES	28
TABLE 15 SAMPLE OF DRUGS DELIVERED THROUGH LIPOSOME NANOTECHNOLOGY	39
TABLE 16 APPROVED NANOCRYSTAL DRUGS	42
TABLE 17 NANOPARTICLES IN BIOTECHNOLOGY APPLICATIONS	45
TABLE 18 NANOBIOSENSOR TECHNOLOGY UNDER DEVELOPMENT	51
TABLE 19 NANOPARTICLES IN DRUG DEVELOPMENT APPLICATIONS	53
TABLE 20 MONOCLONAL ANTIBODY (MAB) DRUGS WITH POTENTIAL FOR USE IN NANOPARTICLE DELIVERY SYSTEMS	54
TABLE 21 SOLID LIPID NANOPARTICLE-REFORMATTED DRUGS	59
TABLE 22 NANOPARTICLES IN DRUG DELIVERY APPLICATIONS	66
TABLE 23 STANDARD ROUTES OF DRUG ADMINISTRATION	78
TABLE 24 NANOPARTICLE TRANSDERMAL PATCH PRODUCTS	79
TABLE 25 TYPES OF NANOPARTICLES SUPPLIED IN DRUG DELIVERY SYSTEMS	82
TABLE 26 NANOCRYSTAL DRUGS APPROVED BY THE FDA	91
TABLE 27 MECHANISMS FOR REMOVAL OF NANOPARTICLES FROM THE BODY	104
TABLE 28 NANOPARTICLE CONTRAST MEDIA USED FOR IN VIVO DIAGNOSTIC IMAGING	107
TABLE 29 CURRENT FDA-APPROVED NANOPARTICLE DRUG DELIVERY SYSTEMS	110
TABLE 30 FDA-APPROVED DRUGS SPECIFICALLY FOR CANCER TREATMENT	112
TABLE 31 FDA-APPROVED DRUGS FOR CENTRAL NERVOUS SYSTEM DISEASES	113
TABLE 32 MAJOR PLAYERS IN NANOPARTICLE DRUG DEVELOPMENT AND FORMULATION MARKET	114
TABLE 33 COMPANY PIPELINE FOR CARDIOVASCULAR NANOPARTICLE DRUGS	115
TABLE 34 COMPANY PIPELINE FOR CNS DISEASE NANOPARTICLE DRUGS	117
TABLE 35 COMPANY PIPELINE FOR GI DISEASE NANOPARTICLE DRUGS	119
TABLE 36 COMPANY PIPELINE FOR INFECTIOUS DISEASE NANOPARTICLE DRUGS	120
TABLE 37 COMPANY PIPELINE FOR CANCER NANOPARTICLE DRUGS	124

TABLE HEADING	PAGE NO.
TABLE 38 COMPANY PIPELINE FOR OPHTHALMIC NANOPARTICLE DRUGS	126
TABLE 39 COMPANY PIPELINE FOR AUTOIMMUNE DISEASE NANOPARTICLE DRUGS	128
TABLE 40 GLOBAL MARKET FOR NANOPARTICLE DRUGS AND DIAGNOSTIC IMAGING, THROUGH 2017 (\$ MILLIONS)	132
TABLE 41 GLOBAL MARKET FOR NANOPARTICLE DRUG DEVELOPMENT AND FORMULATION AND DRUG DELIVERY SYSTEMS, THROUGH 2017 (\$ MILLIONS)	133
TABLE 42 GLOBAL MARKET FOR DIAGNOSTIC IMAGING AND IN VITRO IMAGING, THROUGH 2017 (\$ MILLIONS)	133
TABLE 43 CLINICAL TRIALS FOR NANOPARTICLE DRUGS AND DRUG DELIVERY SYSTEMS	136
TABLE 44 CLINICAL TRIALS FOR NANOPARTICLE DRUGS AND DRUG DELIVERY SYSTEMS	137
TABLE 45 CLINICAL TRIALS FOR NANOPARTICLE DRUGS AND DRUG DELIVERY SYSTEMS	140
TABLE 46 MAJOR LICENSING, COLLABORATIVE PARTNERSHIPS AND MERGER AND ACQUISITION ACTIVITIES	143
TABLE 47 GLOBAL PERCENTAGE SHARE OF PATENTS ISSUED BY GEOGRAPHY, FROM 2008 TO 2011	147
TABLE 48 U.S. PATENTS FOR NANOPARTICLE DRUG DEVELOPMENT	148
TABLE 49 U.S. PATENTS FOR NANOPARTICLE DRUG DELIVERY	148
TABLE 50 U.S. PATENTS FOR QUANTUM DOT TECHNOLOGY APPLIED TO MEDICAL APPLICATIONS	152

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL MARKET FOR NANOPARTICLES IN BIOTECHNOLOGY AND PHARMACEUTICALS, 2010-2017 (\$ MILLIONS)	7